DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x2wz7h/vital_signs) has announced the addition of the "Vital Signs - Healthcare News - The Analyst's Perspective - July 2014" report to their offering.
Earlier this month, five senators wrote to the Food and Drug Administration (FDA) counseling more oversight regarding Lab-Developed Tests (LDTs). They urged the FDA to take prompt action in releasing draft guidance on LDTs so that there can be efficient policing of diagnostic tools before being released into the market.
This issue of Vital Signs, released on August 5, 2014, discusses the Senators plead to the FDA for the quick action regarding draft guidance on laboratory developed tests (LDTs), Synthetic Biology's Series A funding round, Roche's investment in Stratos Genomics, and India's cap on drug prices.
Key Topics Covered:
- Senators Plead to FDA for Quick Action Regarding the Release of Draft Guidance on LDTs
- Synthetic Biology Startup Synlogic Snags $29.4 Million in Series A Funding Round
- Roche Invests in Stratos Genomics for Further Development of Sequencing by Expansion' (SBX) Method
- India Caps Prices of 108 More Medicines; Drugmakers to Take Hit
For more information visit http://www.researchandmarkets.com/research/x2wz7h/vital_signs